Advanced Therapeutics最新文献_第7页

Synthetic Mucus Biomaterials Synergize with Antibiofilm Agents to Combat Pseudomonas aeruginosa Biofilms 合成黏液生物材料与抗菌膜剂协同对抗铜绿假单胞菌生物膜

IF 2.6 4区医学

Advanced Therapeutics Pub Date : 2025-04-29 DOI: 10.1002/adtp.202400359

Sydney Yang, Allison Boboltz, Alexa Stern, Vaidehi Rathi, Gregg Duncan

{"title":"Synthetic Mucus Biomaterials Synergize with Antibiofilm Agents to Combat Pseudomonas aeruginosa Biofilms","authors":"Sydney Yang, Allison Boboltz, Alexa Stern, Vaidehi Rathi, Gregg Duncan","doi":"10.1002/adtp.202400359","DOIUrl":"10.1002/adtp.202400359","url":null,"abstract":"Bacterial biofilms are often highly resistant to antimicrobials causing persistent infections which, when not effectively managed, can significantly worsen clinical outcomes. As such, alternatives to standard antibiotic therapies have been highly sought after to address difficult-to-treat biofilm-associated infections. A biomaterial-based approach using the innate functions of mucins is hypothesized to modulate bacterial surface attachment and virulence can provide a new therapeutic strategy against biofilms. Based on the testing in Pseudomonas aeruginosa biofilms, it is found that synthetic mucus biomaterials can inhibit biofilm formation and significantly reduce the thickness of mature biofilms. In addition, if synthetic mucus biomaterials can work synergistically with DNase and/or α-amylase for enhanced biofilm dispersal is evaluated. Combination treatment with these antibiofilm agents and synthetic mucus biomaterials resulted in up to 2 log reductions in the viability of mature P. aeruginosa biofilms. Overall, this work provides a new bio-inspired, combinatorial approach to address biofilms and antibiotic-resistant bacterial infections.","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"8 5","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/adtp.202400359","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143944970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mimicking Biochemical Traits with a Synthetic Lipid Nanoparticles SARS-COV-2 Model 用合成脂质纳米颗粒模拟SARS-COV-2模型的生化特性

IF 2.6 4区医学

Advanced Therapeutics Pub Date : 2025-04-28 DOI: 10.1002/adtp.202400401

Ignasia Handipta Mahardika, Hyun Park, Eunjin Huh, Changyoon Baek, Shin-Gyu Cho, Kwang-Hwan Jung, Junhong Min, Kwanwoo Shin

{"title":"Mimicking Biochemical Traits with a Synthetic Lipid Nanoparticles SARS-COV-2 Model","authors":"Ignasia Handipta Mahardika, Hyun Park, Eunjin Huh, Changyoon Baek, Shin-Gyu Cho, Kwang-Hwan Jung, Junhong Min, Kwanwoo Shin","doi":"10.1002/adtp.202400401","DOIUrl":"10.1002/adtp.202400401","url":null,"abstract":"The continuous evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) during the global pandemic challenges diagnostic technologies, underscoring the urgent need for quick adaptation and innovation to improve accuracy and efficiency against new variants. The study introduces a synthetic Lipid Nanoparticles (LNPs) model of SARS-CoV-2, utilizing advancements in LNPs vaccine technology to mimic the virus's key biochemical and genetic traits. This liposomal model encapsulates the characteristic SARS-CoV-2 mRNA and nucleocapsid (N) proteins within LNPs and further conjugates with spike (S) protein derivatives on its outer membrane, closely replicating the virus's structure and inducing accurate antigen-antibody responses in diagnostic tests. Furthermore, validation using reverse transcription-quantitative polymerase chain reaction (RT-qPCR) with commercial SARS-CoV-2 reagents confirms its effectiveness in simulating viral RNA amplification. This establishes it as an efficient tool for assessing the diagnostic efficacy of newly marketed diagnostic products. This LNPs model represents a significant advancement in diagnostic development, offering potential for therapeutic and vaccine research while ensuring safety and scalability.","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"8 6","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/adtp.202400401","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144309212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nanoparticles Combining Host-Directed Therapeutics and Antibiotics to Boost Bacterial Killing and Overall Survival of Zebrafish Embryos Infected with Mycobacterium Marinum (Adv. Therap. 4/2025) 结合宿主导向疗法和抗生素的纳米颗粒提高感染海洋分枝杆菌的斑马鱼胚胎的细菌杀伤和总体存活率（ad . therapp . 4/2025）

IF 2.6 4区医学

Advanced Therapeutics Pub Date : 2025-04-18 DOI: 10.1002/adtp.202570009

Gabriela Schäfer, Dongdong Bi, Federico Fenaroli, Andrew M. Thompson, Anno Saris, Matthias Barz

引用次数: 0

Issue Information (Adv. Therap. 4/2025) 发行信息（ad . therapy . 4/2025）

IF 2.6 4区医学

Advanced Therapeutics Pub Date : 2025-04-18 DOI: 10.1002/adtp.202570010

引用次数: 0

Hydroxyapatite Binding Peptide Lipid Nanoparticles for Biomimetic mRNA Delivery to Bone 羟基磷灰石结合肽脂纳米颗粒用于骨仿生mRNA递送

IF 2.6 4区医学

Advanced Therapeutics Pub Date : 2025-04-17 DOI: 10.1002/adtp.202400505

Joshua A. Choe, Jena E. Moseman, Jamie M. Jones, Jacobus C. Burger, Ashley M. Weichmann, Douglas G. McNeel, William L. Murphy

引用次数: 0

Upconversion-Based Remote Deep Brain Modulation for Therapeutic Dissection of Parkinson's Disease 基于上转换的远程脑深部调制治疗帕金森病解剖

IF 2.6 4区医学

Advanced Therapeutics Pub Date : 2025-04-14 DOI: 10.1002/adtp.202400543

Wenchong Zhang, Xudong Lin, Kai Xie, Zixun Wang, Tianying Sun, Zhen Xu, Haibing Yue, Xi Chen, Qinghai Liao, Ming Liu, Wing Ho Yung, Jufang He, Feng Wang, Peng Shi

{"title":"Upconversion-Based Remote Deep Brain Modulation for Therapeutic Dissection of Parkinson's Disease","authors":"Wenchong Zhang, Xudong Lin, Kai Xie, Zixun Wang, Tianying Sun, Zhen Xu, Haibing Yue, Xi Chen, Qinghai Liao, Ming Liu, Wing Ho Yung, Jufang He, Feng Wang, Peng Shi","doi":"10.1002/adtp.202400543","DOIUrl":"10.1002/adtp.202400543","url":null,"abstract":"High frequency deep brain stimulation (DBS) is widely used for improving motor capability in patients with Parkinson's disease (PD). Here, an upconversion-based strategy is described for remote deep brain modulation, which is an all-optical solution for treating PD in rodent animals without any tethering interferences. It is demonstrated that both high frequency stimulation and inhibition of subthalamic nucleus (STN), can improve the motor function of Hemi-Parkinsonian rodent models, potentially providing a specific and flexible therapeutic alternative for treating PD. A multi-modal approach is further taken that combines optogenetics and electrophysiology recording, and found that high frequency optogenetic inhibition of STN work similarly as high frequency activation to rescue the pathologic electrical activity in the motor cortex and restore the motor deficiency in Hemi-Parkinsonian rodents. It is also shown that indirect inhibitory modification of entopeduncular nucleus (EP) within the basal ganglia system, which is induced by either STN inhibition or activation, plays a critical role in the STN-DBS induced therapeutic effects in the Hemi-Parkinsonian animals. These results provide first experimental evidence supporting a working principle of STN-DBS by disruption of anterograde signal transmission along the indirect pathway of basal ganglia, and can be instructive for future clinical treatment of PD with DBS.","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"8 6","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/adtp.202400543","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144309009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nanoparticle-Based Therapeutics for Glioblastoma Multiforme Treatment 基于纳米颗粒的多形性胶质母细胞瘤治疗方法

IF 2.6 4区医学

Advanced Therapeutics Pub Date : 2025-04-08 DOI: 10.1002/adtp.202400546

Paalki Sethi, Shampa Ghosh, Krishna Kumar Singh, Sung Soo Han, Rakesh Bhaskar, Jitendra Kumar Sinha

{"title":"Nanoparticle-Based Therapeutics for Glioblastoma Multiforme Treatment","authors":"Paalki Sethi, Shampa Ghosh, Krishna Kumar Singh, Sung Soo Han, Rakesh Bhaskar, Jitendra Kumar Sinha","doi":"10.1002/adtp.202400546","DOIUrl":"10.1002/adtp.202400546","url":null,"abstract":"Glioblastoma multiforme (GBM) is a grade 4 primary malignant brain neoplasm with a poor prognosis. GBM has an average survival of 12–18 months despite aggressive treatments, such as maximal safe resection, radiation, and chemotherapy with temozolomide. GBM is always associated with high incidences of treatment resistance and recurrence, which is largely driven by glioma stem cells and presents significant therapeutic challenges. The blood–brain barrier (BBB) is the most significant obstacle in treating GBM since it restricts the delivery of therapeutic agents to the tumor site. Recent advancements in nanotechnology offer promising alternatives to overcome such restrictions, enabling targeted drug delivery and significantly reducing systemic toxicity. Additionally, discussing various types of nanoparticles such as liposomes, lipid-based, dendrimers, polymeric, and metallic nanoparticles that have shown promise in preclinical models for GBM treatment has become pertinent. These nanoparticles can attach to glioblastoma cells using antigens and membrane receptors for site-directed drug targeting. Furthermore, nanoparticles have the potential to cross the BBB, enhancing drug delivery and minimizing off-target effects. This review explores the latest advancements in nanoparticle-based therapies and their potential to revolutionize GBM treatment, particularly through the precise targeting and controlled release of therapeutic agents within the tumor microenvironment.","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"8 6","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144308816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Opportunities in Therapeutic mRNA Stabilization: Sequence, Structure, Adjuvants and Vectors 稳定mRNA治疗的机会：序列、结构、佐剂和载体

IF 2.6 4区医学

Advanced Therapeutics Pub Date : 2025-04-08 DOI: 10.1002/adtp.202400537

Joshua A. Choe, Jacobus Burger, Jamie Jones, Apurva Panjla, William L. Murphy

引用次数: 0

Insights on Advances in 3D Bioprinting for Peripheral Nerve Regeneration 生物3D打印用于周围神经再生的研究进展

IF 2.6 4区医学

Advanced Therapeutics Pub Date : 2025-04-03 DOI: 10.1002/adtp.202400506

Nasera Rizwana, Samartha M C, Ashwath Acharya, Goutam Thakur, Manasa Nune, Vipul Agarwal

{"title":"Insights on Advances in 3D Bioprinting for Peripheral Nerve Regeneration","authors":"Nasera Rizwana, Samartha M C, Ashwath Acharya, Goutam Thakur, Manasa Nune, Vipul Agarwal","doi":"10.1002/adtp.202400506","DOIUrl":"10.1002/adtp.202400506","url":null,"abstract":"Peripheral nerve injury is a common injury that impacts the quality of life of the affected individuals. Peripheral nerve is known to regenerate itself when the defect is small. The mechanism of nerve repair and regeneration is complex and is related to neuroimmunomodulation where there is crosstalk between Schwann cells and macrophages which respond to the injury of smaller dimensions immediately. However, regeneration of large defects requires the use of grafts. 3D bioprinting is one such promising technology with which bioengineered nerve conduits can be reproduced for the repair of injured peripheral nerves. This review outlines the mechanism of repair and regeneration of peripheral nerves and provides a detailed description of the latest developments in the fabrication of bioengineered nerve conduits. Further, various bioprinting techniques and bioinks that have been established in vitro for the fabrication of nerve conduits are discussed. In addition, this article aims to look at the in vivo applications of the bioprinted nerve conduits with respect to different types of peripheral nerve models. The challenges and future perspectives involved in fabricating bioprinted functional nerve conduits have also been discussed.","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"8 5","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/adtp.202400506","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143944395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Biomedical Application of Cold Plasma: Navigating Through Plasma Types and Devices by Antimicrobial Effectiveness and Tissue Tolerance 冷等离子体的生物医学应用：通过抗菌有效性和组织耐受性导航等离子体类型和设备

IF 2.6 4区医学

Advanced Therapeutics Pub Date : 2025-03-26 DOI: 10.1002/adtp.202400339

Thomas P. Thompson, Amanda Connelly, Sean Kelly, Ross M. Duncan, Jordanne-Amee Maybin, Carla McDonnell, Autumn Melvage, Laura A. McClenaghan, Aikaterini Dedeloudi, Dimitrios A. Lamprou, Thomas P. Schaer, Paula Bourke, Noreen J. Hickok, Brendan F. Gilmore, Theresa A. Freeman

{"title":"Biomedical Application of Cold Plasma: Navigating Through Plasma Types and Devices by Antimicrobial Effectiveness and Tissue Tolerance","authors":"Thomas P. Thompson, Amanda Connelly, Sean Kelly, Ross M. Duncan, Jordanne-Amee Maybin, Carla McDonnell, Autumn Melvage, Laura A. McClenaghan, Aikaterini Dedeloudi, Dimitrios A. Lamprou, Thomas P. Schaer, Paula Bourke, Noreen J. Hickok, Brendan F. Gilmore, Theresa A. Freeman","doi":"10.1002/adtp.202400339","DOIUrl":"10.1002/adtp.202400339","url":null,"abstract":"This study compares the biofilm efficacy and tissue compatibility of three cold atmospheric plasma devices: J-Plasma (Apyx Medical), Piezo Brush PZ3 (Reylon Plasma GmbH), and Plasma Care (Terraplasma-Medical GmbH). The focus is on surface temperature, pH shifts, and ROS/RNS production, analyzing their effects on bacterial biofilms and tissue both ex vivo and in vivo. Temperature changes, pH shifts, optical emission spectra, and ROS/RNS levels in the liquid phase are measured. Antimicrobial efficacy is tested against biofilms of Pseudomonas aeruginosa and Staphylococcus aureus, grown on 3D-printed poly(ε-caprolactone) discs and titanium sheets. Tissue tolerability is assessed on porcine skin using direct counting for bactericidal effectiveness and SEM for validation, with histological analysis for tissue effects. Plasma Care demonstrated significant bactericidal capabilities (4 logs against S. aureus in 60 s on PCL), minimal tissue disruption, and required short treatment times, functioning independently of target conductivity. Both J-Plasma and Piezo Brush PZ3 show variable outcomes influenced by treatment duration and target surface conductivity, affecting both bactericidal activity and tissue tolerance. The comparative analysis underscores the importance of selecting plasma devices based on specific clinical needs to enhance biofilm management and minimize tissue damage, supporting tailored applications in precision medicine.","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"8 6","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/adtp.202400339","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144309045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0